All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Relative Articles

Comparative evaluation of voglibose versus pioglitazone on glycaemic control and lipid profile in patients of type 2 diabetes mellitus on glimepiride and metformin in punjabi population

Comparative efficacy between glimepiride and metformin in preventing progression of prediabetes to type 2 diabetes

Metformin plus low glimepiride doses improve significantly HOMA IR and HOMAbetaCELL without hyperinsulinemia in patients with type 2 diabetes

Metformin plus low glimepiride doses improve significantly HOMA IR and HOMAbetaCELL without hyperinsulinemia in patients with type 2 diabetes

FORMULATION OF DUAL COMPONENT DRUG DELIVERY OF GLIMEPIRIDE AND METFORMIN HYDROCHLORIDE FOR IMMEDIATE AND SUSTAIN RELEASE

Marked Improvement in Glycemic Control with Exenatide on Addition to Metformin, Sulfonylurea and Insulin Glargine in Type 2 Diabetes Mellitus, a Real World Experience

SIMULTANEOUS ESTIMATION OF GLIMEPIRIDE, PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE BY DERIVATIVE SPECTROPHOTOMETRY METHOD

Effect of vildagliptin as add-on therapy to a low-dose metformin

SIMULTANEOUS ESTIMATION OF PIOGLITAZONE, GLIMEPIRIDE AND GLIMEPIRIDE IMPURITIES IN COMBINATION DRUG PRODUCT BY A VALIDATED STABILITY- INDICATING RP-HPLC METHOD

SIMULTANEOUS ESTIMATION OF PIOGLITAZONE, GLIMEPIRIDE AND GLIMEPIRIDE IMPURITIES IN COMBINATION DRUG PRODUCT BY A VALIDATED STABILITY- INDICATING RP-HPLC METHOD

More...
PLOS ONE  2014 

Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes

DOI: 10.1371/journal.pone.0087799

Full-Text   Cite this paper   Add to My Lib

Abstract:

Aims To compare the commonly prescribed oral anti-diabetic drug (OAD) combinations to use as an add-on therapy with insulin glargine in patients with uncontrolled type 2 diabetes despite submaximal doses of OADs. Methods People with inadequately controlled type 2 diabetes (n = 99) were randomly assigned on a 1:1:1 basis to receive insulin glargin, with fixed doses of glimepiride, metformin, and glimepiride plus metformin. Outcomes assessed included HbA1c, the changes in fasting glucose levels, body weight, serum lipids values, insulin dose and symptomatic hypoglycemia. Results After 24 weeks, HbA1C levels improved from (mean ± SD) 8.5±0.9% to 7.7±0.8% (69.0±10.0 mmol/mol to 60.8±8.6 mmol/mol) with insulin glargine plus metformin, from 8.4±1.0% to 7.7±1.3% (68.8±10.6 mmol/mol to 61.1±14.4 mmol/mol) with insulin glargine plus glimepiride and from 8.7±0.9% to 7.3±0.6% (71.7±9.8 mmol/mol to 56.2±6.7 mmol/mol) with insulin glargine plus glimepirde plus metformin. The decrease in HbA1c was more pronounced with insulin glargine plus glimepiride plus metformin than with insulin glargine plus metformin (0.49% [CI, 0.16% to 0.82%]; P = 0.005) (5.10 mmol/mol [CI, 1.64 to 8.61]; P = 0.005) and insulin glargine plus glimepiride (0.59% [CI, 0.13% to 1.05%]; P = 0.012) (5.87 mmol/mol [CI, 1.10 to 10.64]; P = 0.012) (overall P = 0.02). Weight gain and the risk of hypoglycemia of any type did not significantly differ among the treatment groups. Conclusion The combination therapy of metformin and glimepiride plus glargine insulin resulted in a significant improvement in overall glycemic control as compared with the other combinations. Trial registration information ClinicalTrials.gov, NCT00708578. The approval number of Kangbuk Samsung hospital's institutional review board (IRB): C0825.

References

[1]  Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, et al. (2006) Epidemic obesity and type 2 diabetes in Asia. Lancet 368: 1681–1688. doi: 10.1016/s0140-6736(06)69703-1
[2]  Task Force Team For Basic Statistical Study of Korean Diabetes Mellitus (2007) Report of Task Force Team For Basic Statistical Study of Korean Diabetes Mellitus: Diabetes in Korea 2007. 1st ed. Seoul, Goldfishery.
[3]  Statistics Korea: 2009 statistical results about cause of death. Available: http://www.index.go.kr (updated 2011 Aug 5).
[4]  Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577–1589. doi: 10.1056/nejmoa0806470
[5]  Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364–1379. doi: 10.2337/dc12-0413
[6]  Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P, et al. (2003) Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 26: 2238–2243. doi: 10.2337/diacare.26.8.2238
[7]  Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, et al. (2006) Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 29: 2371–2377. doi: 10.2337/dc06-0564
[8]  Vinik AI, Zhang Q (2007) Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 30: 795–800. doi: 10.2337/dc06-1712
[9]  Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, et al. (2006) Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29: 554–559. doi: 10.2337/diacare.29.03.06.dc05-0695
[10]  Blicklé JF, Hancu N, Piletic M, Profozic V, Shestakova M, et al. (2009) Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7–8% HbA1c levels. The TULIP study. Diabetes Obes Metab 11: 379–386. doi: 10.1111/j.1463-1326.2008.00980.x
[11]  Houlden R, Ross S, Harris S, Yale JF, Sauriol L, et al. (2007) Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 78: 254–258. doi: 10.1016/j.diabres.2007.03.021
[12]  Meneghini LF, Traylor L, Schwartz SL (2010) Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocr Pract 16: 588–599. doi: 10.4158/ep09281.or
[13]  Riddle MC, Rosenstock J, Gerich J (2003) The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080–3086. doi: 10.2337/diacare.26.11.3080
[14]  Yki-J?rvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, et al. (1992) Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327: 1426–1433. doi: 10.1056/nejm199211123272005
[15]  Chow CC, Tsang LW, Sorensen JP, Cockram CS (1995) Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 18: 307–314. doi: 10.2337/diacare.18.3.307
[16]  Yki-J?rvinen H, Ryysy L, Nikkil? K, Tulokas T, Vanamo R, et al. (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 130: 389–396. doi: 10.7326/0003-4819-130-5-199903020-00002
[17]  Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, et al. (2011) Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 35: 431–436. doi: 10.4093/dmj.2011.35.5.431
[18]  American Diabetes Association (2011) Standards of medical care in diabetes-2011. Diabetes Care 34 Suppl 1: S11–61. doi: 10.2337/dc11-s011
[19]  Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, et al. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32: 187–192. doi: 10.2337/dc08-9026
[20]  Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, et al. (2011) Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials. Ann Intern Med 154: 554–559. doi: 10.7326/0003-4819-154-8-201104190-00007
[21]  Aron D, Conlin PR, Hobbs C, Vigersky RA, Pogach L (2011) Individualizing Glycemic Targets in Type 2 Diabetes Mellitus. Ann Intern Med 155: 340–341. doi: 10.7326/0003-4819-155-5-201109060-00025
[22]  Fritsche A, Schweitzer MA, H?ring HU (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138: 952–959. doi: 10.7326/0003-4819-138-12-200306170-00006

Full-Text

comments powered by Disqus